Narcolepsy trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Narcolepsy. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month2 studies across 2 companies, in the next 180 days.
February 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| HLUN-B.CO | H. Lundbeck A/S | A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have NarcolepsyNCT07613710Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | 2027-02-09 | in 173 d | 2026-08-12 |
| 4523.T | Eisai Inc. | A Study to Evaluate the Efficacy and Safety of E2086 in Adults With NarcolepsyNCT07493265Change from Baseline to Week 4 in MSL for E2086 Compared With Placebo Across Four MWTs in Participants With NT1 and NT2 | Phase 2 | Recruiting | 2027-02-14 | in 178 d | 2026-05-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Narcolepsy
most recently updated first33 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IHNCT07625280Change in Epworth Sleepiness Scale (ESS) scores | Phase 3 | Recruiting | Drug: Xywav · Other: Placebo | Narcolepsy, Idiopathic Hypersomnia | 120 | 2026-07-09 | 2027-12-23 | in 490 d | 2026-08-19 |
| HLUN-B.CO | H. Lundbeck A/S | — | A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have NarcolepsyNCT07613710Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: Lu AH69593, Placebo | Narcolepsy | 104 | 2025-06-13 | 2027-02-09 | in 173 d | 2026-08-12 |
| ALKS | Alkermes, Inc. | $8.3B | A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaNCT06767683Incidence of Treatment-Emergent Adverse Events | Phase 2/3 | Recruiting | Drug: ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg, ALKS 2680, 10mg, ALKS 2680, 14mg, ALKS 2680, 18mg | Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia | 256 | 2025-01-27 | Jun 2028 | ≤ 680 d | 2026-08-07 |
| ALKS | Alkermes, Inc. | $8.3B | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1NCT07455383Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level | Phase 3 | Recruiting | Drug: ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo | Narcolepsy Type 1 | 150 | 2026-04-06 | May 2027 | ≤ 284 d | 2026-08-07 |
| ALKS | Alkermes, Inc. | $8.3B | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2NCT07502443Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level | Phase 3 | Recruiting | Drug: ALKS 2680 Dose 1, ALKS 2680 Dose 2, ALKS 2680 Dose 3, Placebo | Narcolepsy Type 2 | 176 | 2026-04-22 | May 2027 | ≤ 284 d | 2026-08-07 |
| ALKS | Alkermes, Inc. | $8.3B | A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)NCT07540897Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level | Phase 3 | Recruiting | Drug: ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo | Narcolepsy Type 1 | 150 | Aug 2026 | Jun 2027 | ≤ 314 d | 2026-08-07 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)NCT03881852results2023-08-24Change From Baseline in the Weekly Average Total Number of Cataplexy Attacks | Phase 2 | Completed | Drug: AXS-12 (Reboxetine), Placebo | Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness | 21 | 2019-04-05 | 2019-11-27actual | — | 2026-06-15 |
| ALKS | Alkermes, Inc. | $8.3B | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)NCT06358950Change in Mean Sleep Latency (MSL) on the Maintenance of Wakefulness Test (MWT) from baseline to Week 6 | Phase 2 | Completed | Drug: ALKS 2680, Placebo | Narcolepsy Type 1 | 92 | 2024-03-24 | 2025-06-19actual | — | 2026-06-10 |
| VRTX | Vertex Pharmaceuticals Incorporated | $133.9B | A Phase 1, First-in-human Study of VX-433NCT07584434Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: VX-433, Placebo, Midazolam, Bupropion | Narcolepsy Type 1 (NT1) | 118 | 2026-05-21 | 2027-03-05 | in 197 d | 2026-06-08 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With NarcolepsyNCT05059223Frequency of cataplexy attacks | Phase 3 | Completed | Drug: AXS-12 (reboxetine), Placebo | Narcolepsy, Cataplexy, Excessive Daytime Sleepiness | 90 | 2021-09-15 | 2024-03-15actual | — | 2026-05-28 |
| 4523.T | Eisai Inc. | $8.7B | A Study to Evaluate the Efficacy and Safety of E2086 in Adults With NarcolepsyNCT07493265Change from Baseline to Week 4 in MSL for E2086 Compared With Placebo Across Four MWTs in Participants With NT1 and NT2 | Phase 2 | Recruiting | Drug: E2086, Placebo | Narcolepsy | 64 | 2026-03-26 | 2027-02-14 | in 178 d | 2026-05-14 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With NarcolepsyNCT05869773results2026-04-24Change From Baseline to End of Treatment (EOT) Visit on the 24-hour Average Systolic Blood Pressure (SBP) in mmHg | Phase 4 | Completed | Drug: JZP258 | Narcolepsy | 155 | 2023-06-26 | 2025-02-25actual | — | 2026-04-24 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1NCT06961266Mean sleep latency of the first 4 sessions of the Maintenance of Wakefulness Test | Phase 1 | Terminatedsponsor's stated reason: The study was terminated based on a business decision by the Sponsor. | Drug: JZP441, Matching Placebo | Narcolepsy | 6 | 2025-05-13 | 2026-01-29actual | — | 2026-04-06 |
| ALKS | Alkermes, Inc. | $8.3B | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2NCT06555783Change in Mean Sleep Latency (MSL) on the Maintenance Wakefulness Test (MWT) | Phase 2 | Completed | Drug: ALKS 2680, Placebo | Narcolepsy Type 2 | 93 | 2024-07-26 | 2025-11-11actual | — | 2026-02-27 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)NCT05113745Long-term safety as measured by the incidence of treatment-emergent adverse events | Phase 3 | Completed | Drug: AXS-12 (reboxetine), Placebo | Narcolepsy, Cataplexy, Excessive Daytime Sleepiness | 68 | 2021-10-20 | 2024-11-15actual | — | 2025-11-13 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or NarcolepsyNCT05875974Epworth Sleepiness Scale (ESS) Total Score in Participants With IH and Narcolepsy Treated With XYWAV | Phase 4 | Completed | Drug: JZP258 (XYWAV) | Idiopathic Hypersomnia, Narcolepsy | 207 | 2023-07-27 | 2025-03-13actual | — | 2025-07-17 |
| 4523.T | Eisai Inc. | $8.7B | A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1NCT06462404Mean Sleep Latency (MSL) as Assessed by the 4 Maintenance of Wakefulness Tests (MWTs) for E2086 Versus Placebo at Day 1 | Phase 1 | Completed | Drug: E2086, E2086 Placebo, Active Comparator, Active Comparator Placebo | Narcolepsy Type 1 (NT1) | 22 | 2024-06-20 | 2025-03-17actual | — | 2025-06-04 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Child and Adolescent Registry for Participants With NarcolepsyNCT04899947observationalImprove Understanding of Natural History of Pediatric Narcolepsy | — | Recruiting | — | Narcolepsy | 500 | 2020-10-10 | 2024-10-01 | — | 2024-08-15 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | SUNOSI® (Solriamfetol) Pregnancy RegistryNCT06413420observationalLong-term Safety | — | Recruiting | Drug: Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants · Other: No treatment | Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring | 1,731 | 2019-07-31 | Sep 2029 | ≤ 1,137 d | 2024-05-14 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | An Interventional Safety Switch Study (Segue Study) of XYWAV in NarcolepsyNCT04794491results2024-01-09Change in Weekly Rate of Cataplexy Attacks | Phase 4 | Completed | Drug: JZP-258 | Narcolepsy | 62 | 2021-03-22 | 2022-11-15actual | — | 2024-01-09 |
| AXSM | Axsome Therapeutics, Inc. | $11.3B | Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral AdministrationNCT05008341Maximum Concentration (Cmax) of Solriamfetol in Breast Milk and Plasma | Phase 1 | Completed | Drug: Solriamfetol 150 mg Oral Tablet | Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence, Excessive Sleepiness, Postpartum | 6 | 2021-08-27 | 2022-04-15actual | — | 2023-04-14 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in NarcolepsyNCT04803786observationalNumber of Participants with Increased/Decreased/Same Dose Transitioning from Xyrem to Xywav | — | Completed | Drug: Transition from Xyrem to Xywav | Narcolepsy | 110 | 2021-04-09 | 2022-02-24actual | — | 2022-06-30 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Web-based Observational Study of Patient-reported Outcomes in Adults With NarcolepsyNCT02769780observationalDescriptive epidemiology of type 1 and type 2 narcolepsy | — | Completed | — | Narcolepsy | 1,500 | 2015-07-08 | 2021-08-09actual | — | 2022-04-05 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime SleepinessNCT01485770results2021-07-06Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) Following Two Weeks of Treatment With ADX-N05 vs. Two Weeks of Treatment With Placebo | Phase 2 | Completed | Drug: ADX-N05, Placebo | Narcolepsy | 33 | Dec 2011 | May 2012actual | — | 2021-07-06 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With NarcolepsyNCT01681121results2014-09-11Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) for ADX-N05 300 mg vs. Placebo at Last Assessment. | Phase 2 | Completed | Drug: ADX-N05, Placebo | Narcolepsy | 93 | Sep 2012 | Aug 2013actual | — | 2021-05-28 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in NarcolepsyNCT02806908results2021-01-13Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax) | Phase 2 | Completed | Drug: JZP-110, Placebo | Narcolepsy, Excessive Sleepiness | 24 | Jun 2016 | 2019-05-19actual | — | 2021-01-13 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With CataplexyNCT03030599results2020-11-12Change in Weekly Number of Cataplexy Attacks | Phase 3 | Completed | Drug: JZP-258 · Other: Placebo | Narcolepsy With Cataplexy | 201 | 2017-03-14 | 2019-01-24actual | — | 2020-11-12 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"NCT02348593results2019-07-23Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12 | Phase 3 | Completed | Drug: JZP-110, Placebo oral tablet | Narcolepsy | 239 | May 2015 | Feb 2017actual | — | 2019-07-23 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"NCT02348632results2019-06-25Change in Epworth Sleepiness Scale (ESS) Score | Phase 3 | Completed | Drug: JZP-110 | Narcolepsy, Obstructive Sleep Apnea | 645 | May 2015 | Dec 2017actual | — | 2019-06-25 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With CataplexyNCT02221869results2019-04-30Change in Weekly Number of Cataplexy Attacks | Phase 3 | Completed | Drug: Xyrem | Narcolepsy With Cataplexy | 106 | 2014-10-01 | Feb 2017actual | — | 2019-04-30 |
| PFE | Pfizer | $155.3B | A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With NarcolepsyNCT01006122results2014-05-09Change From Baseline in Maintenance of Wakefulness Test (MWT) Score at Day 21 of Stable Dosing Phase | Phase 2 | Completed | Drug: Placebo, PF-03654746 | Excessive Daytime Sleepiness, Narcolepsy | 95 | Nov 2009 | Nov 2010actual | — | 2014-05-09 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Trial of Xyrem® (Sodium Oxybate) for the Treatment of NarcolepsyNCT00132873results2013-11-25Adverse Experiences | Phase 3 | Completed | Drug: Xyrem (sodium oxybate) oral solution | Narcolepsy | 59 | Oct 2004 | Sep 2007actual | — | 2013-11-25 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in NarcolepsyNCT00066170results2011-11-30Daytime Sleep Latency as Measured by the Maintenance of Wakefulness Test (MWT) | Phase 3 | Completed | Drug: Xyrem, Xyrem Placebo, Modafinil at established dose, Modafinil (Placebo) | Narcolepsy | 231 | Apr 2003 | Jul 2004actual | — | 2011-12-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Narcolepsy is matched — 6 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Narcolepsy
- Narcolepsy Type 1
- Narcolepsy Type 2
- Cataplexy
- Narcolepsy Type 1 (NT1)
- Narcolepsy With Cataplexy
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Narcolepsy” (a text search, wider than this page)